Islamic Hospital
Amman, Jordan
NCT Number: NCT05442801
The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations. This will be a prospective double-blinded randomized clinical trial (RCT), multi center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.
Looking for future studies?
Notify Me3 year–16 year
All sexes
Interventional
Phase 4
Amman, Jordan
Refractive errors assessment especially in pediatric populations is usually affected by the accommodative spasm and possibly a myopic shift in the results. Spasm of accommodation become evident as pesudomyopia or latent hyperopia. Therefore, cycloplegic refraction using cycloplegic drugs is an effective way to reduce fluctuation in accommodation or spasm of ciliary muscle. The drug of choice should have a rapid onset, appropriate cyclopegic effect and minimum side effects. Cyclopentolate and Tropicamide are well known drugs used for accommodation relaxation. Cyclopentolate is widely accepted drug of first choice for patients of all ages. Its cycloplegic effects begins at 25-75 min after administration of the drop and recovery appears through 6-24 h later.6 Ocular side effects may include irritation, lacrimation, allergic blepharoconjunctivitis, conjunctival hyperemia, and increase in intraocular pressure. Some of its systemic side effects are drowsiness, ataxia, disorientation, incoherent speech, restlessness, and visual hallucinations. Tropicamide, as an alternative, is a synthetic analog of tropic acid and is known as a safe agent for cycloplegic refraction. It characterized by a rapid onset and the cycloplegia effect appears 20-30 min after administration. Its recovery appears 6 h later with safer profile compared to cyclopentolate. Several studies have been conducted to compare the cycloplegic effect of these two agents and different results have been reported. Because of inconsistencies in the previous reported results, this randomized clinical trial was conducted to compare the cycloplegic effect between cyclopentolate and tropicamide among pediatric populations (aged between 3 and 16).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Well known eye drop used for cycloplegic refraction among children.
Other names: Cyclogel
Well known eye drop used for cycloplegic refraction among children.
Other names: Mydriacil
Time frame: 3 months
To study the SE of each drug and compare the mean difference between cyclopentolate and tropicamide
Time frame: 3 months
To measure the depth of cycloplegia mean difference between cyclopentolate and tropicamide
Islamic Hospital, Jordan
Other
Tropicamide Versus Cyclopentolate Objective Refraction in Pediatric Population
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05585736
Cycloplegia
Damietta, New Damietta, Egypt
View Trial DetailsNCT04075591
Eye Diseases, Refractive Error
Los Angeles, California, United States
View Trial DetailsNCT00320593
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial DetailsNCT07693673
Cornea, Corneal Diseases
Sohag, Sohag Governorate, Egypt
View Trial Details